To further evaluate PIK3CA or PTEN mutations as predictive for response to the combination, we evaluated the effects of combining rapamycin with pemetrexed with other human NSCLC cell lines that do not have PIK3CA or PTEN mutations (H1703 and PC-9 (formerly known as PC-14) cells). The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.